ClinicalTrials.gg
CompletedNCT01472185Updated Oct 24, 2014Results posted

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Ranolazine and Placebo in Type 2 Diabetes Mellitus, sponsored by Gilead Sciences. Completed at 159 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-10-24.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
465
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ranolazine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Ranolazine · Diabetes Mellitus, Type 2.

Enrollment
2nd of 11
465 · median 47
Started
2011
with 2 others
Phase 3
4 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
9 of 11
Gilead Sciences

Among the 11 studies testing ranolazine in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About ranolazine

Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when given as monotherapy on glycemic control in subjects with type 2 diabetes mellitus (T2DM) who were inadequately controlled with diet and exercise alone and who are treatment naive to antihyperglycemic therapy or have not received antihyperglycemic therapy in the 90 days (or thiazolidinediones [TZDs] for at least 24 weeks) prior to screening, and to characterize the relationship between HbA1c reduction and other glycemic parameters in subjects with T2DM.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Males and females, 18 to 75 years old, inclusive
  • Documented history of T2DM
  • Treatment naïve to antihyperglycemic therapy or having received no prior treatment with antihyperglycemic therapy for at least 90 days (TZDs for at least 24 weeks) prior to screening
  • (BMI) 25 kg/m2 to 45 kg/m2 inclusive at screening
  • 7% - 10%, inclusive at screening and at the end of the Qualifying Period (Day 14 +2 days)
  • Fasting serum glucose (FSG) of ≥ 130 mg/dL (7.2 mmol/L) and ≤ 240 mg/dL (13.3 mmol/L) at screening and at the end of the Qualifying Period (Day 14 +2 days). A one-time central laboratory re-test of FSG is allowed in subjects with an initial central laboratory FSG ≥ 125 mg/dL (6.9 mmol/L) and \< 130 mg/dL (7.2 mmol/L) who are otherwise eligible as determined by the investigator.
  • Fasting serum C-peptide ≥ 0.8 ng/mL at screening
  • Able and willing to comply with all study procedures during the course of the study
  • Females of must have a negative pregnancy test at screening and must agree to use highly effective methods from screening throughout the duration of the Treatment Period and for 14 days following the last dose of study drug
  • At least 80% compliant with dosing during the Qualifying Period

Exclusion criteria

Exclusion Criteria:

  • History of or current diagnosis of type 1 diabetes mellitus
  • History of diabetic ketoacidosis, ketosis-prone diabetes, or hyperosmolar hyperglycemic coma
  • History of a severe episode of hypoglycemia (≥ 1 episode within 3 months prior to screening or ≥ 2 episodes within 6 months prior to screening), defined as hypoglycemia requiring 3rd party assistance to actively administer carbohydrate, glucagon, or other resuscitative actions due to severe impairment in consciousness or behavior
  • complications of diabetes that, in the judgment of the investigator, would make the subject unsuitable to participate in this study
  • History of any clinically significant cardiovascular or cerebrovascular event (eg, myocardial infarction [MI], acute coronary syndrome [ACS], recent coronary revascularization [including coronary artery bypass graft procedures or percutaneous coronary intervention], or ischemic stroke) ≤ 3 months prior to screening
  • Inadequately controlled or unstable hypertension as defined by systolic blood pressure (SBP) > 160 mmHg or diastolic blood pressure (DBP) > 100 mmHg at screening and randomization
  • Prolonged > 500 msec by at screening, a personal or family history of QTc prolongation, congenital long QT syndrome, or subjects who are receiving drugs that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents, erythromycin, and certain antipsychotics (eg, ziprasidone)
  • History of bariatric surgery at any time in the past or any other surgery \< 2 months before screening, or planning to undergo surgery during the study. Subjects with a planned minor surgery may be enrolled upon approval by the Medical Monitor.
  • Any other hospitalization in the 14 days prior to screening or planned hospitalization at any time during the study
  • Significant weight change (± 5%) \< 2 months prior to screening or on a weight-loss program and is not in the maintenance phase at screening
  • Severe renal impairment, defined as an estimated (eGFR) by the Modification of Diet in Renal Disease (MDRD) equation \< 30 mL/min/1.73 m2 at screening or undergoing any type of dialysis at screening or planning to undergo any type of dialysis during the course of the study.
  • History of liver cirrhosis ( Class A, B or C)
  • Active liver disease and/or significant abnormal liver function defined as (AST) > 3x (ULN) and/or alanine aminotransferase (ALT) > 3x ULN and/or serum total > 2.0 mg/dL
  • History of cancer (except non-melanomic skin cancers or cervical in situ) within 5 years prior to screening
  • History of alcohol or other drug abuse \< 12 months prior to screening
  • Any other clinically significant existing medical or psychiatric condition, including clinically significant laboratory abnormalities, or one requiring further evaluation that, in the opinion of the investigator, could interfere with conduct of the study or interpretation of the data
  • Prior treatment with open-label ranolazine or known or intolerance to ranolazine or any of its
  • Treatment with strong or moderate cytochrome (CYP)3A inhibitors or P-glycoprotein (P-gp) inhibitors within 14 days prior to randomization
  • Treatment with inducers or P-gp inducers within 14 days prior to randomization
  • Treatment with CYP3A4 substrates with a narrow therapeutic range (eg, cyclosporine, tacrolimus, sirolimus) within 14 days prior to randomization
  • Treatment with simvastatin at a daily dose > 20 mg or lovastatin at a daily dose > 40 mg, within 14 days prior to randomization
  • Weight-loss medication or anti-obesity medication (prescription or nonprescription) \< 3 months prior to screening
  • Treatment with niacin > 200 mg daily; if receiving ≤ 200 mg daily, should be on stable doses for ≥ 90 days prior to screening and for the duration of the study
  • Expected or current treatment with systemic (oral or injectable) for > 14 days from screening through the end of the Treatment Period. Topical or inhaled corticosteroid formulations are permitted at any time during the study
  • If receiving thyroid replacement therapy, should be on stable doses for at least 6 weeks prior to randomization
  • \< 12 g/dL for males; or \< 11 g/dL for females, at screening
  • Participation in another clinical study involving an drug or device \< 30 days prior to screening; participation in another clinical study involving an antihyperglycemic therapy \< 90 days prior to screening
  • Donation of blood \< 2 months prior to screening; plans to donate blood while participating in the study
  • Females who are pregnant or breastfeeding
  • Other condition(s) that, in the opinion of the investigator, would compromise the safety of the subject, would prevent compliance with the study protocol (including the ability to comply with Mixed Meal Tolerance Test [MMTT]), or would compromise the quality of the clinical study
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
465 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days. Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks. Participants were required to maintain their diet and exercise regimen.

    Drug: Placebo · Behavioral: Diet · Behavioral: Exercise

  • Experimental
    Ranolazine

    Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days. Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks. Participants were required to maintain their diet and exercise regimen.

    Drug: Ranolazine · Drug: Placebo · Behavioral: Diet · Behavioral: Exercise

Interventions

  • Ranolazine tablets administered orally twice daily.

    Also known as: Ranexa®

  • DrugPlacebo

    Placebo to match ranolazine administered orally twice daily.

  • BehavioralDiet

    Participants are instructed to continue the diet regimen prescribed by their physician.

  • BehavioralExercise

    Participants are instructed to continue the exercise regimen prescribed by their physician.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

    The average (mean) change from baseline in HbA1c at Week 24 was analyzed.

    Time frame: Baseline; Week 24

Secondary outcomes

  1. Change From Baseline in Fasting Serum Glucose at Week 24

    The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.

    Time frame: Baseline; Week 24

  2. Percentage of Participants With HbA1c < 7% at Week 24

    Time frame: Week 24

  3. Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24

    The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed. Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at time \[T\] = 120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations and analyzed based on the randomized treatment regardless of actual treatment received.

    Time frame: Baseline; Week 24

  4. Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24

    The average (mean) change from baseline in incremental change of 2-hour postprandial serum glucose at Week 24 was analyzed.

    Time frame: Baseline; Week 24

07

Results

Posted Oct 15, 2014

Participant flow

Participants were enrolled at a total of 113 study sites in the United States, South Africa, Europe, and Russia. The first participant was screened on 15 November 2011. The last participant observation occurred on 21 October 2013.

Participant flow — Overall Study
MilestonePlaceboRanolazine
Started232233
Completed198199
Not completed3434
Withdrew: Randomized but not treated01
Withdrew: Adverse event other than hyperglycemia310
Withdrew: Hyperglycemia52
Withdrew: Investigator's discretion31
Withdrew: Lost to follow-up41
Withdrew: Protocol violation51
Withdrew: Subject noncompliance815
Withdrew: Subject withdrew consent63

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

The average (mean) change from baseline in HbA1c at Week 24 was analyzed.

Time frame:
Baseline; Week 24
Reported as:
Mean · percent of HbA1c in blood
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
percent of HbA1c in bloodPlaceboRanolazine
HbA1c at Week 247.70 ± 1.1837.26 ± 1.101
Change from baseline in HbA1c at Week 24-0.27 ± 1.027-0.80 ± 1.020
Statistical analysis
  • Placebo vs Ranolazine · Mixed Effects Model Analysis · p = < 0.0001 (P-value is from a mixed effects model including terms for baseline HbA1c value, treatment group, visit week, and treatment by visit week interaction. Unstructured covariance matrix was used.) · Difference in least squares mean (lsm): -0.56 · 95% CI -0.76 to -0.36The estimation (LSM) is of the placebo-corrected change from baseline.
SecondaryChange From Baseline in Fasting Serum Glucose at Week 24

The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.

Time frame:
Baseline; Week 24
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Serum Glucose at Week 24
mg/dLPlaceboRanolazine
Change From Baseline in Fasting Serum Glucose at Week 241 ± 42.2-7 ± 37.5
SecondaryPercentage of Participants With HbA1c < 7% at Week 24
Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c < 7% at Week 24
percentage of participantsPlaceboRanolazine
Percentage of Participants With HbA1c < 7% at Week 2425.641.2
SecondaryChange From Baseline in 2-hour Postprandial Serum Glucose at Week 24

The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed. Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at time \[T\] = 120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations and analyzed based on the randomized treatment regardless of actual treatment received.

Time frame:
Baseline; Week 24
Reported as:
Mean · mg/dL
Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24
mg/dLPlaceboRanolazine
Change From Baseline in 2-hour Postprandial Serum Glucose at Week 242 ± 65.1-19 ± 53.8
SecondaryChange From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24

The average (mean) change from baseline in incremental change of 2-hour postprandial serum glucose at Week 24 was analyzed.

Time frame:
Baseline; Week 24
Reported as:
Mean · mg/dL
Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24
mg/dLPlaceboRanolazine
Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24-1 ± 47.7-12 ± 37.9

Adverse events

Collected over Up to 24 Weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—7/232 (3%)31/232 (13.4%)
Ranolazine—6/232 (2.6%)28/232 (12.1%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPlaceboRanolazine
Angina unstableCardiac disorders1/2320/232
Atrial fibrillationCardiac disorders0/2321/232
Atrioventricular block second degreeCardiac disorders1/2320/232
Myocardial ischaemiaCardiac disorders0/2321/232
Sinoatrial blockCardiac disorders1/2320/232
Infected dermal cystInfections and infestations0/2321/232
Lower limb fractureInjury, poisoning and procedural complications1/2320/232
Upper limb fractureInjury, poisoning and procedural complications1/2320/232
HyperglycaemiaMetabolism and nutrition disorders0/2321/232
Non-small cell lung cancer stage ivNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2320/232
Most frequent other events
Most frequent other events
EventPlaceboRanolazine
HyperglycaemiaMetabolism and nutrition disorders23/23218/232
HeadacheNervous system disorders10/23212/232

Baseline characteristics

Baseline characteristics are reported for the Safety Analysis Set following randomization. The Safety Analysis Set includes randomized participants who received at least one dose of study treatment, analyzed based on actual treatment received.

Age, Continuous
Age, Continuous(years)PlaceboRanolazineTotal
Mean56 ± 9.355 ± 9.556 ± 9.4
Age, Customized
Age, Customized(participants)PlaceboRanolazineTotal
< 65 years197199396
≥ 65 years353368
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRanolazineTotal
Female113123236
Male119109228
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRanolazineTotal
Hispanic or Latino312960
Not Hispanic or Latino201202403
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboRanolazineTotal
Asian10919
Black or African-American10919
White209213422
Other213
Not Permitted101
Region of Enrollment
Region of Enrollment(participants)PlaceboRanolazineTotal
Serbia022
United States6256118
Hungary12921
Slovakia81321
Poland71118
Ukraine393675
Romania101121
South Africa111324
Russian Federation8382165
Body Mass Index
Body Mass Index(kg/m^2)PlaceboRanolazineTotal
Mean32.8 ± 4.8532.8 ± 4.7532.8 ± 4.80
Glycosylated hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c)(percent HbA1c in blood)PlaceboRanolazineTotal
Mean8.01 ± 0.7278.06 ± 0.7328.04 ± 0.729

3 further baseline measures are reported on the registry.

08

Study locations

159 sites
  • Thunderbird Internal Medicine/Clinical Research Advantage
    Glendale, Arizona 85306, United States
  • Central Phoenix Medical Clinic
    Phoenix, Arizona 85020, United States
  • Desert Sun Clinical Research, LLC
    Tucson, Arizona 85710, United States
  • Eclipse Clinical Research
    Tucson, Arizona 85745, United States
  • North Central Arkansas Medical Associates
    Mountain Home, Arkansas 72653, United States
  • Paul W. Davis, MD, Private Practice
    Pine Bluff, Arkansas 71603, United States
  • Southland Clinical Research Center, Inc.
    Fountain Valley, California 92708, United States
  • Global Research Management
    Glendale, California 91205, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Spectrum Clinical Research Institute, Inc
    Moreno Valley, California 92553, United States
  • Sacramento Heart and Vascular Medical Associates
    Sacramento, California 95825, United States
  • Clearview Medical Research LLC
    Santa Clarita, California 91350, United States
  • Infosphere Clinical Research
    West Hills, California 91307, United States
  • Boca Raton Clinical Research Associates, Inc
    Boca Raton, Florida 33432, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • Florida Research Network, LLC
    Gainesville, Florida 32605-4253, United States
  • A G A Clinical Trials
    Hialeah, Florida 33012, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • NextPhase Clinical Trials, Inc.
    Miami Beach, Florida 33140, United States
  • Precision Research Organization
    Miami Lakes, Florida 33016, United States
  • Baptist Diabetes Associates
    Miami, Florida 33156, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Florida Institute for Clinical Research LLC
    Orlando, Florida 32822, United States
  • Regenerate Clinical Trials
    South Miami, Florida 33143, United States
  • Synergy Therapeutic Partners
    Atlanta, Georgia 30127, United States
  • CTL Research
    Eagle, Idaho 83616, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • LaPorte County Institute for Clinical Research
    Michigan City, Indiana 46360, United States
  • Clinical Trials Management, LLC
    Metairie, Louisiana 70006, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • IRC Clinics, Inc
    Towson, Maryland 21204, United States
  • Associated Internal Medicine Specialists, P.C.
    Battle Creek, Michigan 49015, United States
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • University of New Mexico Clinical and Translational Science Center
    Albuquerque, New Mexico 87131, United States
  • Clinical Research Solution
    New York, New York 10016, United States
  • PMG Research of Charlotte
    Charlotte, North Carolina 28202, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • PMG Research of Salisbury
    Salisbury, North Carolina 28144, United States
  • Clinical Inquest Center, Ltd.
    Beavercreek, Ohio 45431, United States
  • Infinity Research Group, LLC
    Oklahoma City, Oklahoma 73103, United States
  • Blair Medical Associates, Inc, Station Medical Center
    Altoona, Pennsylvania 16602, United States
  • Southeastern Research Associates, Inc.
    Taylors, South Carolina 29687, United States
  • HCCA Clinical Research Solutions
    Columbia, Tennessee 38401, United States
  • HCCA Clinical Research Solution
    Jackson, Tennessee 38305, United States
  • New Phase Research & Development
    Knoxville, Tennessee 37923, United States
  • HCCA Clinical Research Solutions
    Smyrrna, Tennessee 37167, United States
  • The University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • Excel Clinical Research, LLC
    Houston, Texas 77081, United States
  • Texas Center for Drug Development, PA
    Houston, Texas 77081, United States
  • Humble Cardiology Associates
    Humble, Texas 77338, United States
  • Juno Research, LLC
    Katy, Texas 77450, United States
  • Cetero Research
    San Antonio, Texas 78237, United States
  • Discovery Clinical Trials
    San Antonio, Texas 78258, United States
  • Highland Clinical Research
    Salt Lake City, Utah 84124, United States
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
  • Burke Internal Medicine & Research
    Burke, Virginia 22015, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Nemocnice s poliklinikou Havirov
    Havirov, Moravskoslezsky kraj 736 01, Czech Republic
  • Drug Research Center
    Balatonfüred, 8230, Hungary
  • Synexus Hungary Ltd
    Budapest, 1036, Hungary
  • Markhot Ferenc Hospital
    Eger, 3300, Hungary
  • Kanizsai Dorottya Hospital
    Nagykanizsa, 8800, Hungary
  • Borbanya Praxis Kft., Outpatient Clinic
    Nyíregyháza, 4400, Hungary
  • Medifarma 98
    Nyíregyháza, 4400, Hungary
  • Zala County Hospital
    Zalaegerszeg, 08900, Hungary
  • NZOZ Regionalna Poradnia Diabetologiczna
    Wroclaw, Dolnoslaskie 50-127, Poland
  • NZOZ Centrum Badan Klinicznych
    Wroclaw, Dolnoslaskie 50-349, Poland
  • SPZOZ Uniwersytecki Szpital Kliniczny Nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Łodzi, Oddział Kliniczny Diabetologii
    Lodz, Lodzkie 90-153, Poland
  • NZOZ Centrum Medyczne Szpital Sw. Rodziny
    Lodz, Lodzkie 90-302, Poland
  • NZOZ Polimedica
    Zgierz, Lodzkie 95-100, Poland
  • LANDA - Specjalistyczne Gabinety Lekarskie
    Krakow, Malopolskie 30-015, Poland
  • NZOZ Centrum Badan Klinicznych Oswiecim
    Oswięcim, Malopolskie 32-600, Poland
  • NZOZ PrimaMED
    Kielce, Swietokrzyskie 25-364, Poland
  • NZOZ Centrum Osteporozy i Chorob Kostno-Stawowych J.Badurski Sp.j.
    Bialystok, 15-461, Poland
  • Leszek Romanowski Barbara Romanowska "DIABET" Centrum Medyczne s.c.
    Chrzanów, 32-500, Poland
  • NZOZ Specjalistyczna Przychodnia Medyczna Atopia
    Krakow, 31-159, Poland
  • NZOZ Cereo-Med Sp. z o.o.
    Lodz, 92-003, Poland
  • Specjalistyzny Ośrodek Lecznicz-Badawczy
    Ostroda, 14-100, Poland
  • Miedzyleski Szpital Specjalistyczny w Warszawie
    Warszawa, 04-749, Poland
  • Spital Clinic Judetean de Urgenta Oradea Stationarul 1
    Oradea, Jud Bihor 410169, Romania
  • Vitadiab SRL - Cabinet Medical Dr. Barabas Alina SRL
    Brasov, Jud Brasov 500269, Romania
  • Consultmed SRL
    Iasi, Jud. Iasi 700547, Romania
  • CMI Diabet Nutritie Boli Metabolice Dr. Pop Lavinia
    Baia Mare, Jud. Maramures 430123, Romania
  • CMI Morosanu V. Magdalena
    Galati, Judetul Galati 800371, Romania
  • Spitalul Clinic Judetean de Urgenta "Sf. Apostol Andrei" Galati
    Galati, Judetul Galati 800578, Romania
  • Diabmed Dr. Popescu Alexandrina SRL
    Ploiesti, Judetul Prahova 100163, Romania
  • Tehnomed Trading Srl
    Bucharest, 020354, Romania
  • Institutul de Diabet, Nutritie si Boli Metabolice "Dr. N. C. Paulescu"
    Bucuresti, 020042, Romania
  • O.D. Medica Srl
    Bucuresti, 020725, Romania
  • Centru Medical Dr. Negrisanu
    Timisoara, jud. Timis, 300456, Romania
  • 3rd Central Military Clinical Hospital named after A.A.Vishnevskogo
    Arkhangelskoe, 143420, Russian Federation
  • GOU VPO "Chita State Medical Academy" of Minzdravsocrazvitie RF
    Chita, 672090, Russian Federation
  • "Clinic of New Medical Technology" Company Limited
    Dzerzhinskiy, 140091, Russian Federation
  • The Urals State Medical Academy
    Ekaterinburg, 620102, Russian Federation
  • Kemerovo Regional Clinical Hospital
    Kemerovo, 650066, Russian Federation
  • "Krasnoyarsk State Medical University n.a. Prof. V.F. Voyno-Yasenetsky
    Krasnoyarsk, 660062, Russian Federation
  • State Healthcare Institution of Moscow "Cardiologival Dispensary #2 of Management Department of South Administrative District"
    Moscow, 117556, Russian Federation
  • Central Clinical Hospital of Russian Academy of Sciences
    Moscow, 117593, Russian Federation
  • Medical Sanitary Unit of Minestry of Internal Affairs of Russia in Moscow
    Moscow, 127299, Russian Federation
  • Moscow City Clinical Hospital #63
    Moscow, 129090, Russian Federation

Showing the first 100 of 159 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Eckel RH, Henry RR, Yue P, Dhalla A, Wong P, Jochelson P, Belardinelli L, Skyler JS. Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes. Diabetes Care. 2015 Jul;38(7):1189-96. doi: 10.2337/dc14-2629. Epub 2015 Jun 6. PubMed 26049552 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year after primary completion. A results delay was requested in Dec 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2011
First posted
Nov 16, 2011
Start
Nov 2011
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results delay requested
Dec 12, 2013
Results first posted
Oct 15, 2014
Last update
Oct 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01472185
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 16, 2011
Start date
Nov 2011
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Oct 15, 2014
Last update
Oct 24, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion